2-溴-5-氯-1,3-二氟苯 | 883546-16-5

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 烃类卤化物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-5-氯-1,3-二氟苯
• 中文别名: 4-溴-1-氯-3,5-二氟苯
• 英文名称: 2-bromo-5-chloro-1,3-difluorobenzene
• CAS: 883546-16-5
• 化学式: C₆H₂BrClF₂
• 分子量: 227.436
• InChiKey: OUMNGNRBHZGAMH-UHFFFAOYSA-N

物化性质

• 沸点：
  176℃
• 密度：
  1.805
• 闪点：
  60℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2903999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-5-chloro-1,3-difluorobenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-5-chloro-1,3-difluorobenzene
CAS number: 883546-16-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H2BrClF2
Molecular weight: 227.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-5-氯-1,3-二氟苯 在 硫酸 、 异丙基氯化镁 、 硝酸 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 47.83h， 生成 N-[3-chloro-6-(5-chloro-3-oxo-1,2-tetramethylene-4-pyrazolin-4-yl)-5-fluoro-2-nitrophenyl]-L-alanine methyl ester
  参考文献：
  名称：

  ピラゾリノン誘導体、その製造法及びそれを有効成分として含有する除草剤

  摘要：

  提供优良的除草效果，作为除草剂有效成分有用的化合物。显示为式（1）的吡唑啉衍生物，其制备方法以及包含其作为有效成分的除草剂。[R1为卤素原子；R2和R3共同形成三亚甲基基（-（CH2）3-）、四亚甲基基（-（CH2）4-）、五亚甲基基（-（CH2）5-）或二氧化乙撑基（-（CH2）2O（CH2）2-）；R4为H或卤素原子；R5为卤素原子；Ar为3-氧代-1,4-苯并噁嗪-5-基、2,2-二氟-3-氧代-1,4-苯并噁嗪-5-基或3,4-二氢-2-氧代喹诺噁啉-5-基]【选择图】无

  公开号：

  JP2016060742A
• 作为产物：
  描述：

  4-溴-3,5-二氟苯胺 在 copper(l) chloride 、 copper dichloride 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以81%的产率得到2-溴-5-氯-1,3-二氟苯
  参考文献：
  名称：

  ピラゾリノン誘導体、その製造法及びそれを有効成分として含有する除草剤

  摘要：

  提供优良的除草效果，作为除草剂有效成分有用的化合物。显示为式（1）的吡唑啉衍生物，其制备方法以及包含其作为有效成分的除草剂。[R1为卤素原子；R2和R3共同形成三亚甲基基（-（CH2）3-）、四亚甲基基（-（CH2）4-）、五亚甲基基（-（CH2）5-）或二氧化乙撑基（-（CH2）2O（CH2）2-）；R4为H或卤素原子；R5为卤素原子；Ar为3-氧代-1,4-苯并噁嗪-5-基、2,2-二氟-3-氧代-1,4-苯并噁嗪-5-基或3,4-二氢-2-氧代喹诺噁啉-5-基]【选择图】无

  公开号：

  JP2016060742A

文献信息

• [EN] MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS<br/>[FR] INHIBITEURS MITOCHONDRIALES POUR LE TRAITEMENT DE TROUBLES PROLIFÉRATIFS
  申请人：BASILEA PHARM INT AG

  公开号：WO2019072978A1

  公开（公告）日：2019-04-18

  The invention provides compounds of formula (I) or pharmaceutically acceptable salt thereof wherein ring A represents group A-I, A-II or A-III. Al represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A2 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A3 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A4 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A5 represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A6 represents -C(R4c)(R4c)- or -C(R4c)=; A7 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A8 represents -C(R4a)(R4a)-, -N(R4b)-, -O- or -S-; A9 represents -C(R4c)(R4c)- or -0-; A10 represents -C(R4c)(R4c)- or -0-; A11 represents -C(R4c)(R4c)- or -0-; A12 represents -C(R4a)(R4a)-, -O- or -S-; wherein group A-I, group A-II and group A-III de not contain adjacent oxygen atoms, adjacent oxygen and sulfur atoms or adjacent oxygen and nitrogen atoms or a moiety selected from the group consisting of N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S, wherein in each case the carbon atom in the N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S moiety is saturated; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a, R4b and R4c are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.

  该发明提供了式(I)的化合物或其药学上可接受的盐，其中环A代表A-I、A-II或A-III基团。Al代表-C(R4a)(R4a)-、-C(R4a)= -N(R4b)-、-N= -O-或-S-；A2代表-C(R4c)(R4c)-、-C(R4c)=或-0-；A3代表-C(R4c)(R4c)-、-C(R4c)=或-0-；A4代表-C(R4a)(R4a)-、-C(R4a)= -N= -O-或-S-；A5代表-C(R4a)(R4a)-、-C(R4a)= -N(R4b)-、-N= -O-或-S-；A6代表-C(R4c)(R4c)-或-C(R4c)=；A7代表-C(R4a)(R4a)-、-C(R4a)= -N= -O-或-S-；A8代表-C(R4a)(R4a)-、-N(R4b)-、-O-或-S-；A9代表-C(R4c)(R4c)-或-0-；A10代表-C(R4c)(R4c)-或-0-；A11代表-C(R4c)(R4c)-或-0-；A12代表-C(R4a)(R4a)-、-O-或-S-；其中A-I基团、A-II基团和A-III基团不含相邻的氧原子、相邻的氧和硫原子或相邻的氧和氮原子，或从N-C-N、N-C-S、S-C-S、O-C-N、O-C-O和O-C-S组成的基团中选择的基团，其中在每种情况下，N-C-N、N-C-S、S-C-S、O-C-N、O-C-O和O-C-S基团中的碳原子是饱和的；B1、B2、B3和B4分别代表C(R3)或N，其中B1、B2、B3和B4中最多有两个代表N；n为1或2；R1、R2、R3、R4a、R4b和R4c如索引中所定义，以及使用这些化合物治疗增殖性疾病，特别是癌症的方法。
• Ligand-Free Cu-Catalyzed Cyanation of Aryl Halides with K4[Fe(CN)6] in Water
  作者：Yunlai Ren、Shuang Zhao、Xinzhe Tian、Zhifei Liu、Jianji Wang、Weiping Yin

  DOI：10.2174/157017809789869573

  日期：2009.10.1

  A simple methodology for Cu-catalyzed cyanation of aryl halides with K4[Fe(CN)6] was developed with water as the solvent in conjunction with ligand-free Cu(OAc)2·H2O as the catalyst. The suggested methodology is applicable to cyanation of a wide range of aryl iodides and activated aryl bromides, and allows the catalyst to be reused six times with a very slight change in the catalytic activity.

  开发了一种简单的方法，以K4[Fe(CN)6]为氰化试剂，利用水作为溶剂，无配体的Cu(OAc)2·H2O作为催化剂，进行铜催化的芳基卤化物氰化反应。该方法适用于多种芳基碘化物和活化的芳基溴化物的氰化反应，并且该催化剂可重复使用六次，催化活性变化非常小。
• Mild and General Conditions for Negishi Cross-Coupling Enabled by the Use of Palladacycle Precatalysts
  作者：Yang Yang、Nathan J. Oldenhuis、Stephen L. Buchwald

  DOI：10.1002/anie.201207750

  日期：2013.1.7

  A wide range of biaryls were synthesized by palladium‐catalyzed Negishi cross‐couplings at ambient temperature or with low catalyst loading. This protocol features the use of a recently reported aminobiphenyl palladacycle precatalyst to generate the catalytically active XPhosPd0 species. Significantly, a wide range of challenging heterocyclic and polyfluorinated aromatic substrates can be employed

  在环境温度或低催化剂负载量下，通过钯催化的根岸交叉偶联合成了多种联芳基化合物。该协议的特点是使用最近报道的氨基联苯钯环预催化剂来生成具有催化活性的 XPhosPd 0物质。值得注意的是，可以采用各种具有挑战性的杂环和多氟化芳香族底物来获得高产率的产品。
• PIPERIDINE DERIVATIVE
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20190040039A1

  公开（公告）日：2019-02-07

  The purpose of the present invention is to provide a compound having excellent antibacterial activity against mycobacterium tuberculosis , multidrug-resistant tuberculosis bacteria, and/or non-tuberculous acid-fast bacteria. A compound represented by formula [I]: (in the formula, each symbol is as described in the attached specification), or a salt thereof can be used to diagnose, prevent, and/or treat tuberculosis.

  本发明的目的是提供一种对结核分枝杆菌、多药耐药结核菌和/或非结核性抗酸杆菌具有优异抗菌活性的化合物。可以利用由化学式[I]表示的化合物（在该化学式中，每个符号如所附规范所述），或其盐来诊断、预防和/或治疗结核病。
• Evaluation of the Structure–Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-<i>a</i>]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies
  作者：Killian Oukoloff、Goodwell Nzou、Carmine Varricchio、Bobby Lucero、Thibault Alle、Jane Kovalevich、Ludovica Monti、Anne-Sophie Cornec、Yuemang Yao、Michael J. James、John Q. Trojanowski、Virginia M.-Y. Lee、Amos B. Smith、Andrea Brancale、Kurt R. Brunden、Carlo Ballatore

  DOI：10.1021/acs.jmedchem.0c01605

  日期：2021.1.28

  demonstrated that brain-penetrant microtubule (MT)-stabilizing compounds, including the 1,2,4-triazolo[1,5-a]pyrimidines, hold promise as candidate treatments for Alzheimer’s disease and related neurodegenerative tauopathies. Triazolopyrimidines have already been investigated as anticancer agents; however, the antimitotic activity of these compounds does not always correlate with stabilization of MTs in cells

  对 tau 和 Aβ 斑块转基因小鼠模型的研究表明，脑渗透性微管 (MT) 稳定化合物，包括 1,2,4-三唑[1,5- a]嘧啶，有望成为阿尔茨海默病和相关神经退行性 tau 蛋白病的候选治疗方法。三唑并嘧啶已作为抗癌剂进行了研究。然而，这些化合物的抗有丝分裂活性并不总是与细胞中 MTs 的稳定性相关。事实上，我们实验室以前的研究确定了在 C6 上连接的片段在确定三唑并嘧啶是否促进 MT 稳定或相反地破坏细胞中的 MT 完整性方面的关键作用。为了进一步阐明构效关系 (SAR) 并确定神经退行性疾病的潜在改善 MT 稳定候选物，设计、合成和评估了一套全面的 68 种三唑并嘧啶同系物，这些同系物在 C6 和/或 C7 处具有结构修饰。